1201 related articles for article (PubMed ID: 30914826)
1. Navigating metabolic pathways to enhance antitumour immunity and immunotherapy.
Li X; Wenes M; Romero P; Huang SC; Fendt SM; Ho PC
Nat Rev Clin Oncol; 2019 Jul; 16(7):425-441. PubMed ID: 30914826
[TBL] [Abstract][Full Text] [Related]
2. Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy.
Fan C; Zhang S; Gong Z; Li X; Xiang B; Deng H; Zhou M; Li G; Li Y; Xiong W; Zeng Z; Li X
Sci China Life Sci; 2021 Apr; 64(4):534-547. PubMed ID: 32815067
[TBL] [Abstract][Full Text] [Related]
3. Metabolic checkpoints and novel approaches for immunotherapy against cancer.
Li Y; Tang J; Jiang J; Chen Z
Int J Cancer; 2022 Jan; 150(2):195-207. PubMed ID: 34460110
[TBL] [Abstract][Full Text] [Related]
4. Immune-mediated anti-tumor effects of metformin; targeting metabolic reprogramming of T cells as a new possible mechanism for anti-cancer effects of metformin.
Bahrambeigi S; Shafiei-Irannejad V
Biochem Pharmacol; 2020 Apr; 174():113787. PubMed ID: 31884044
[TBL] [Abstract][Full Text] [Related]
5. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy.
Pitt JM; Marabelle A; Eggermont A; Soria JC; Kroemer G; Zitvogel L
Ann Oncol; 2016 Aug; 27(8):1482-92. PubMed ID: 27069014
[TBL] [Abstract][Full Text] [Related]
6. Combination cancer immunotherapies tailored to the tumour microenvironment.
Smyth MJ; Ngiow SF; Ribas A; Teng MW
Nat Rev Clin Oncol; 2016 Mar; 13(3):143-58. PubMed ID: 26598942
[TBL] [Abstract][Full Text] [Related]
7. Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy.
Li J; Eu JQ; Kong LR; Wang L; Lim YC; Goh BC; Wong ALA
Molecules; 2020 Oct; 25(20):. PubMed ID: 33092283
[TBL] [Abstract][Full Text] [Related]
8. Manipulating Metabolic Alterations and their Consequences to Unleash the Potential of Antitumor Immunotherapy.
Zhu X; Zhu L; Wu Y
Curr Protein Pept Sci; 2022; 23(9):585-601. PubMed ID: 35726423
[TBL] [Abstract][Full Text] [Related]
9. The cancer metabolic reprogramming and immune response.
Xia L; Oyang L; Lin J; Tan S; Han Y; Wu N; Yi P; Tang L; Pan Q; Rao S; Liang J; Tang Y; Su M; Luo X; Yang Y; Shi Y; Wang H; Zhou Y; Liao Q
Mol Cancer; 2021 Feb; 20(1):28. PubMed ID: 33546704
[TBL] [Abstract][Full Text] [Related]
10. Rationale for anti-CD137 cancer immunotherapy.
Makkouk A; Chester C; Kohrt HE
Eur J Cancer; 2016 Feb; 54():112-119. PubMed ID: 26751393
[TBL] [Abstract][Full Text] [Related]
11. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.
Wang H; Franco F; Ho PC
Trends Cancer; 2017 Aug; 3(8):583-592. PubMed ID: 28780935
[TBL] [Abstract][Full Text] [Related]
12. Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy.
Bader JE; Voss K; Rathmell JC
Mol Cell; 2020 Jun; 78(6):1019-1033. PubMed ID: 32559423
[TBL] [Abstract][Full Text] [Related]
13. Targeting T cell metabolism in the tumor microenvironment: an anti-cancer therapeutic strategy.
Yin Z; Bai L; Li W; Zeng T; Tian H; Cui J
J Exp Clin Cancer Res; 2019 Sep; 38(1):403. PubMed ID: 31519198
[TBL] [Abstract][Full Text] [Related]
14. Metabolic Modulation of Immunity: A New Concept in Cancer Immunotherapy.
Guerra L; Bonetti L; Brenner D
Cell Rep; 2020 Jul; 32(1):107848. PubMed ID: 32640218
[TBL] [Abstract][Full Text] [Related]
15. Combination cancer immunotherapy and new immunomodulatory targets.
Mahoney KM; Rennert PD; Freeman GJ
Nat Rev Drug Discov; 2015 Aug; 14(8):561-84. PubMed ID: 26228759
[TBL] [Abstract][Full Text] [Related]
16. Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy.
Wei G; Zhang H; Zhao H; Wang J; Wu N; Li L; Wu J; Zhang D
Cancer Lett; 2021 Jul; 511():68-76. PubMed ID: 33957184
[TBL] [Abstract][Full Text] [Related]
17. Immunometabolism: A new target for improving cancer immunotherapy.
Guo C; Chen S; Liu W; Ma Y; Li J; Fisher PB; Fang X; Wang XY
Adv Cancer Res; 2019; 143():195-253. PubMed ID: 31202359
[TBL] [Abstract][Full Text] [Related]
18. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.
Galon J; Bruni D
Nat Rev Drug Discov; 2019 Mar; 18(3):197-218. PubMed ID: 30610226
[TBL] [Abstract][Full Text] [Related]
19. Autophagy in tumour immunity and therapy.
Xia H; Green DR; Zou W
Nat Rev Cancer; 2021 May; 21(5):281-297. PubMed ID: 33758415
[TBL] [Abstract][Full Text] [Related]
20. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
